8:50 am Chair’s Opening Remarks

  • Megan Coder Executive Director, Digital Therapeutics Alliance

Robust Clinical Trial Design & Execution


The digital therapeutics space is full with confusion on true validation levels of various digital therapeutics, making it more important than ever to ensure trials are designed correctly and robustly. Through interactive discussion, this session tackles the critical steps for clinically evaluated digital therapeutics, highlighting the importance of robust trial methods in representing the evidence-driven route for external approval.

9:00 am DTx Clinical Imperatives

  • Anil Jina Chief Medical Officer, Akili Interactive


• Setting a high bar for clinical validation
• DTx trial design and methodology
• Leveraging digital for real-world data

9:30 am Improving User Experience to Ensure Rich Data & Reduce Attrition

  • Olivier Jarry Chief Commercial Officer & President, DarioHealth


• The trap of believing “build it (digitally) and they will come”
• Consistent and intense participation of the patient is required to run clinical trials, enact lifestyle changes and deliver outcomes
• Techniques for robust engagement (e.g. attention capture, rewards, gamification)

10:00 am Speed Networking

10:30 am Morning Refreshments

11:00 am Digital Therapeutics From the Lens of Traditional Pharmaceutical Industry

  • Chihiro Hosoya BD/VC Head, Rx+ Business Accelerator, Astellas Venture Management


• Astellas Rx+ introduction
• What Astellas values in evaluating BD / investment opportunities in digital therapeutics field
• Opportunities and challenges for pharma in making entry to digital therapeutics

11:15 am Running a Pharma Study with a Digital Therapeutic: Our Experiences


• In this talk we’ll share our experiences, the good the bad and the ugly
• Running our first proof-of-concept clinical trial at Novartis with the use of a digital therapeutic

11:45 am Q&A Session with the Expert Speakers


Key topics to be discussed include:

• Incorporating reliable placebos and blinding to trials, building validity for later stage approval from reimbursement and regulatory systems
• Asking the right questions to find the ‘active ingredient’: What is truly influencing our results?
• System development for improving user experience for a range of therapeutic modalities

12:30 pm Networking Lunch

Reimbursement & Commercial Considerations for Informed Development Decisions & Successful Market Access & Adoption


As the digital therapeutics space evolves, an understanding of the reimbursement landscape is critical for informed development decisions. This session will tackle the widespread lack of understanding surrounding the payer approach and reimbursement pathways, as well as critical commercial strategies to prepare for streamlined financial success.

1:30 pm Digital Therapeutics: Software as Prescription Medical Treatments


• Hear what healthcare executives need to know and what is being missed
• Learn how prescription digital therapeutics (PDTs) will be integrated in to care protocols
• Understand how reimbursement, medical policies, and drug formularies will change as PDTs enter the market

2:00 pm Key Considerations for Developing Strategic System & Payer Partnerships to Effectively Scale Digital Therapeutics


• Identifying and engaging the right partner at the right time
• Structuring partnerships to facilitate a path to scale
• Establishing partnerships that yield mutual gains
• What it takes to be organizationally and operationally ready to partner and scale

2:30 pm Overcoming Barriers to Scale in Digital Therapeutics

  • Chris Hogg Chief Commercial Officer, Propeller Health


• The barriers we’ve overcome so far, and what’s next for the industry
• Understanding the current reimbursement path for digital therapeutics
• Overcoming infrastructure issues related to distribution
• Determining the best path to scale: B2C, B2B, B2B2C and everything in between

3:00 pm Afternoon Refreshments

3:30 pm The Role of Clinical Evidence in Adoption by Payers, Providers & Patients


• Learn how evidence influences customers in different ways and is a critical component of your brand story to drive adoption
• Learn how clinical evidence was used with these groups through real world case studies
• Uncovering the secrets of the medical policy: Understanding the process to validate technologies

4:00 pm Digital Therapeutics Reimbursement: Charting New Territory

  • Mark Bini Vice President, Innovation & Member Experience, Express Scripts


• Understanding payer incentives
• Focusing on value
• Preventing data overload for providers
• Integrating digital and traditional therapies

4:30 pm Q&A Session with the Expert Speakers

  • Megan Coder Executive Director, Digital Therapeutics Alliance
  • Aaron Gani Founder & Chief Executive Officer, BehaVR
  • Joel Sangerman Chief Commercial Officer, Click Therapeutics
  • Mark Bini Vice President, Innovation & Member Experience, Express Scripts
  • Everett Crosland Senior VP, Commercial, AppliedVR


• Understanding evidence requirements of public vs private insurers
• Clarifying the reimbursement categories within the US market, from drug to psychosocial services, and their impact on DTx development and commercialization
• Developing direct to consumer models: Comparing prescribable to over-the-counter routes for consumer accessibility
• Exploring recent guidelines issued by NICE and Germany, and what these mean for international growth

5:15 pm End of Day One